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-Synuclein is a major component of Lewy bodies, the
pathological hallmark of Parkinson disease, dementia
with Lewy bodies, and related disorders. Misfolding and
aggregation of -synuclein is thought to be a critical
cofactor in the pathogenesis of certain neurodegenera-
tive diseases. In the current study, we investigate the
role of the carboxyl terminus of Hsp70-interacting pro-
tein (CHIP) in -synuclein aggregation. We demonstrate
that CHIP is a component of Lewy bodies in the human
brain, where it colocalizes with -synuclein and Hsp70.
In a cell culture model, endogenous CHIP colocalizes
with -synuclein and Hsp70 in intracellular inclusions,
and overexpression of CHIP inhibits -synuclein inclu-
sion formation and reduces -synuclein protein levels.
We demonstrate that CHIP can mediate -synuclein deg-
radation by two discrete mechanisms that can be dis-
sected using deletion mutants; the tetratricopeptide re-
peat domain is critical for proteasomal degradation,
whereas the U-box domain is sufficient to direct
-synuclein toward the lysosomal degradation pathway.
Furthermore, -synuclein, synphilin-1, and Hsp70 all co-
immunoprecipitate with CHIP, raising the possibility of
a direct -synuclein-CHIP interaction. The fact that the
tetratricopeptide repeat domain is required for the ef-
fects of CHIP on -synuclein inclusion morphology,
number of inclusions, and proteasomal degradation as
well as the direct interaction of CHIP with Hsp70 impli-
cates a cooperation of CHIP and Hsp70 in these pro-
cesses. Taken together, these data suggest that CHIP
acts a molecular switch between proteasomal and lyso-
somal degradation pathways.
-Synuclein is a major component of Lewy bodies (LBs)1
found in Parkinson disease, dementia with Lewy body dis-
ease (DLB), the Lewy body variant of Alzheimer disease, and
glial cytoplasmic inclusions found in multiple system atrophy
(1–3). In these neurodegenerative disorders, collectively re-
ferred to as synucleinopathies, LBs are characterized by ab-
normal fibrillar aggregates of -synuclein protein in the cy-
toplasm of selective populations of neurons and glial cells
(4–7). Three different missense mutations in the -synuclein
gene (7–9) as well as triplication of the -synuclein gene (10)
have been shown to cause dominant inherited Parkinson
disease in a small subset of human patients. Moreover, over-
expression of -synuclein in transgenic mice, flies, and viral
vector-transduced rodents leads to -synuclein pathology ac-
companied by neuronal dysfunction, the loss of synaptic ter-
minals, and/or neuronal cell loss (11–16). These studies im-
plicate a molecular pathological role of -synuclein in Lewy
body-related neurodegenerative diseases.
In living cells, various stresses cause unfolded or misfolded
proteins to accumulate. Heat shock proteins recognize mis-
folded proteins and aid refolding. In addition to chaperone
activity, heat shock proteins have been shown to facilitate
degradation of highly misfolded proteins by transferring them
to the ubiquitin proteasome degradation system (17–21). Mo-
lecular chaperones and their functions in protein quality
control have been implicated in several neurodegenerative
diseases (22–25). It has recently been reported that overex-
pression of the molecular chaperone Hsp70 prevents dopam-
inergic neuronal loss induced by -synuclein in Drosophila
(16) and prevents accumulation of Triton X-100-insoluble
-synuclein in -synuclein transgenic mice (26).
For proper function, chaperones rely on interactions with
co-chaperones to control the cycle of ATP binding, hydrolysis,
and substrate binding (27). The carboxyl terminus of Hsp70-
interacting protein (CHIP) has been recently identified as a
co-chaperone protein (28) and is composed of three major do-
mains: an amino-terminal three tandem tetratricopeptide re-
peat (TPR) domain, a highly charged central domain, and a
carboxyl-terminal U-box domain. Recent in vitro data demon-
strate that CHIP interacts with Hsc70/Hsp70 through its TPR
domain and adjacent charged domain and regulates chaperone
activity (28). The U-box domain of CHIP has a modified ring
finger motif similar to that found in ubiquitin ligases. This
suggests that CHIP is involved in ubiquitin-dependent protein
degradation pathways. In fact, CHIP has been reported to be a
bona fide E3 ubiquitin ligase (29), and supporting data have
shown that CHIP promotes ubiquitinylation of chaperone sub-
strates like the glucocorticoid receptor (30), cystic fibrosis
transmembrane conductance regulator (31), Raf-1 protein ki-
nase (21), and ErbB2 (32) in a U-box-dependent manner and
can direct them to degradation through the proteasome. Fur-
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thermore, CHIP has been demonstrated to cooperate with
Hsp70/90 and induce ubiquitination of the microtubule-associ-
ated protein tau (33). Recent data have shown that CHIP
interacts directly with Parkin and positively regulates Parkin
E3 ubiquitin ligase activity, resulting in protection from neu-
rotoxicity induced by unfolded protein stress in the endoplas-
mic reticulum of dopaminergic neurons (34, 35). Taken to-
gether, CHIP functions in protein quality control by shifting
the molecular chaperone system between its refolding machin-
ery and degradation.
In the current study, we provide evidence that CHIP plays a
role in -synuclein aggregation and degradation. CHIP colocal-
izes with -synuclein and Hsp70 in Lewy bodies and also in a
cell culture model of -synuclein inclusions. Overexpression of
CHIP reduces -synuclein aggregation and increases
-synuclein degradation in cell culture. We also demonstrate
that CHIP can mediate -synuclein degradation via both the
proteasomal degradation pathway and the lysosomal degrada-
tion pathway and that specific domains of CHIP are required to
direct -synuclein to mediate these degradation decisions.
EXPERIMENTAL PROCEDURES
Cell Culture, Transient Transfection, and Drug Treatment—Human
H4 neuroglioma cells (HTB-148; ATCC) were maintained in Opti-MEM
(Invitrogen) supplemented with 10% fetal bovine serum. H4 cells were
plated in 4-well chamber slides or 60-mm dishes 24 h prior to transfec-
tion. Cells were transfected with an equimolar ratio of DNA constructs
using Superfect (Qiagen, Chatsworth, CA) according to the manufac-
turer’s instructions. 10 g/ml N-acetyl-Leu-Leu-norleucinal (ALLN)
(Sigma) in dimethyl sulfoxide was added to the culture medium for the
last 16–18 h of a 48-h transfection, and 25 mM ammonium chloride was
added for the last 22 h of a 24-h transfection.
Plasmid Constructs—The -synuclein expression constructs used in
this study have been described previously. Briefly, 93 amino acids of the
N-terminal region of enhanced green fluorescent protein were fused to
the carboxyl terminus of -synuclein in pcDNA3.1, resulting in an
-synuclein enhanced green fluorescent protein deletion construct
(WTSynEGFP155, now called Syn-T), or the cDNA encoding WT
-synuclein was cloned into pSI expression vector (Promega) (36). Over-
expression of -synuclein was detected via immunofluorescence and not
direct fluorescence. Synphilin-1 cDNA (37) was cloned into pcDNA
3.1/V5-His-Topo expression vector such that synphilin-1 has a C-termi-
nal V5/His tag as described (38). Human Hsp70 cDNA was kindly
provided by J.-C. Plumier (Massachusetts General Hospital) and
subcloned into pcDNA3.1. For CHIP expression, pcDNA3-CHIP,
pcDNA3-CHIPU (residues 196–303 deleted), and pcDNA3-CHIPTPR
(residues 32–145 deleted) constructs were described previously (30).
Myc-tagged CHIP constructs were produced by subcloning CHIP,
CHIPU, or CHIPTPR into pcDNA3.1-Myc/His (B) (Invitrogen).
Immunohistochemistry/Immunocytochemistry and Confocal Micros-
copy—Human midbrain tissue from four subjects, with a pathological
diagnosis of DLB was obtained along with temporal cortex of two cases
of Alzheimer disease and two control cases from the Harvard Brain
Tissue Resource Center in the Massachusetts Alzheimer Disease Re-
search Center. The tissue was fixed in 4% paraformaldehyde and sec-
tioned for free-floating, 40-m sections. Transiently transfected cells
were fixed in 4% paraformaldehyde for 10 min after 24- or 48-h trans-
fection. After fixation, human brain sections or transfected cells were
permeabilized with 0.5% Triton X-100 in Tris-buffered saline (pH 7.4)
for 20 min at room temperature and blocked in 1.5% normal goat serum
(Jackson ImmunoResearch, West Grove, PA) for 1 h at room tempera-
ture. DLB tissue was triple-stained with a mouse anti--synuclein
antibody (H3C, monoclonal 1:3000; gift from Julia George, University of
Illinois), rabbit anti-CHIP antibody (polyclonal, 1:500) (28), and bioti-
nylated anti-Hsp70 antibody (polyclonal, 1:500; StressGen, Victoria,
Canada). Transfected cells were stained with a mouse anti--synuclein
antibody (syn-1, monoclonal, 1:1000; BD Transduction Laboratories),
CHIP antibody and biotinylated Hsp70 antibody. Primary antibodies
were incubated overnight at 4 °C followed by secondary antibodies
(Cy3, 1:500 (Jackson ImmunoResearch); Bodipy, 1:500 (Molecular
Probes, Inc., Eugene, OR); fluorescein isothiocyanate, 1:500 (Molecular
Probes, Inc.); or Cy5, 1:500 (Jackson ImmunoResearch)) for 1 h at room
temperature. Immunostaining was observed using a Bio-Rad MRC-
1024 confocal microscope (Cy3: excitation at 568 nm, emission at 605
nm; Bodipy, fluorescein isothiocyanate: excitation at 488 nm, emission
at 522 nm; Cy5: excitation at 647 nm, emission at 680 nm). Control
experiments demonstrated no signal from any of the secondary anti-
bodies in the absence of the corresponding primary antibody. For the
preabsorption experiment, 30 g of recombinant CHIP protein was
incubated with anti-CHIP antibody (final dilution of 1:500) in PBS for
2 h at 37 °C and overnight at 4 °C. The mixture was centrifuged, and
supernatant was used for immunostaining.
Quantitation of Lewy Bodies and Cells Containing Inclusions—-
Synuclein and CHIP immunoreactivity was observed using a 20 ob-
jective and -synuclein immunopositive Lewy bodies were counted. The
percentage of Lewy bodies stained with CHIP was determined by as-
sessing the number of CHIP-immunopositive Lewy bodies of 25 Lewy
bodies immunopositive for -synuclein in each case examined. The
number of transfected H4 cells containing -synuclein-immunopositive
inclusions were assessed following immunocytochemistry using a fluo-
rescence microscope with a 20 objective as follows. Cells were as-
sessed by an observer blind to the transfection conditions. A transfected
cell containing inclusions was scored on the presence of detectable
-synuclein immunopositive inclusions compared with background
(which in all cases was negligible). A cell was considered positive for
inclusions regardless of the size or number of inclusions. Cells from two
different wells of four-well slides were assessed, and 300–400 cells were
counted for each experiment. The percentage of transfected cells con-
taining inclusions was recorded.
Coimmunoprecipitation and Western Blot Analysis—For immuno-
precipitation, H4 cells were harvested 24 h after transfection and lysed
in lysis buffer: 50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 0.3% CHAPS, 10
mM NaF, 100 M sodium orthovanadate, 1 mM phenylmethylsulfonyl
fluoride, and protease inhibitor mixture (Roche Applied Science) for 1 h
on ice. Cell lysates were centrifuged at 10,000 rpm for 10 min at 4 °C,
and supernatant was used for immunoprecipitation using protein G-
agarose and rat anti-Myc antibody (JAC6; Serotec, Oxford, UK) over-
night at 4 °C. Immunoprecipitates were washed with lysis buffer three
times and loaded onto 10–20% Tris/glycine gels (Invitrogen). Protein
was transferred to Immobilon-P membrane (Millipore Corp.) and
blocked in blocking buffer (Lycor, Lincoln, NE) for 1 h prior to the
addition of primary antibody (mouse monoclonal anti--synuclein,
syn-1, 1:1000; rabbit polyclonal anti-Hsp70, 1:10,000 (StressGen, Vic-
toria, Canada); mouse monoclonal anti-V5, 1:2000 (Invitrogen); mouse
monoclonal anti-Myc, 9E10, 1:1000 (Developmental Studies Hybridoma
Bank, University of Iowa)) at room temperature for 1–2 h or overnight
at 4 °C. Followed by three TBS-T washes, infrared fluorescent labeled
secondary antibodies (IRDye 800 anti-rabbit or IRDye 700 anti-mouse,
1:2000, Rockland Immunochemicals (Gilbertsville, PA)) were incubated
at room temperature for 1 h, and immunoblots were processed using the
Odyssey infrared imaging system (Lycor).
For Western blot analysis, cells were washed with cold phosphate-
buffered saline 24 or 48 h after transfection, lysed on ice in lysis buffer
(50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, pH 8.0, 0.1%
Triton X-100, protease inhibitor mixture), and sheared 10 times
through a 301⁄2-gauge needle. Protein concentration was determined
using a Lowry protein assay. 30 g of each cell lysate was loaded onto
10–20% Tris/glycine gels (Invitrogen), and mouse anti--synuclein, rab-
bit anti-Hsp70, and mouse anti-actin (AC-40, 1:500, Sigma) were used
for Western blot analysis. Immunoblots were processed and quantified
using the Odyssey infrared imaging system as described above (Lycor,
Lincoln, NE) or processed using ECL (Amersham Biosciences) and
quantified using ImageJ software.
Protein Degradation Assay—H4 tet-off cells stably overexpressing
Syn-T were maintained in the absence of doxycycline (Syn-T expression
“on”). 24 h following transfection of synphilin-1 and either empty vector
or CHIP, cells were treated with 1 g/ml doxycycline to turn off Syn-T
expression. Cells were harvested at specific time points, and Syn-T
expression was detected by Western blot analysis.
Statistical Analysis—Statistical analysis for comparison of groups
was performed by analysis of variance, with Fisher’s probability of least
significant differences post hoc test for significance. The comparison of
samples with a hypothesized mean of 1 was carried out using a one-
group Student’s t test with the statistical software, Statview (SAS
Institute Inc., Cary, NC). For the protein degradation assay, linear
regression analysis was performed to determine the independent effect
of CHIP expression on Syn-T levels.
RESULTS
CHIP Localizes in Lewy Bodies—Several heat shock pro-
teins, including Hsp70 and Hsp40, have been found to colocal-
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ize with -synuclein in LBs and Lewy neurites (LNs) in Par-
kinson disease and DLB (16, 39). Taken together with the fact
that ubiquitin is also a prominent component of the vast ma-
jority of LBs (40), this implicates protein refolding and degra-
dation as a central process in the pathology of these diseases.
In this study, we tested the hypothesis that CHIP also accu-
mulates in LBs. To this end, we examined four pathologically
confirmed cases of DLB for the presence of CHIP in LBs. LBs
and LNs were positively identified using the monoclonal anti
-synuclein antibody H3C. Interestingly, 87%  7.08 (S.D.,
n  4) of nigral LBs were also immunopositive for CHIP using
a polyclonal CHIP antibody (Fig. 1A). Consistent with our
previous findings, 70% of LBs were immunopositive for
Hsp70 (39). By contrast, substantially less CHIP immunoreac-
tivity was detected in LNs. In control brain and pathologically
confirmed cases of Alzheimer disease, no LB-like inclusions
were detected with either antibodies to -synuclein or CHIP,
although as previously reported, neurofibrillary tangles were
CHIP-immunoreactive (33). The specificity of the CHIP anti-
body was affirmed by preabsorption with recombinant CHIP
protein. Tissue sections and CHIP-overexpressing H4 cells
were immunostained with preabsorbed CHIP antibody as well
as secondary antibody alone in the absence of primary anti-
body. CHIP immunoreactivity was drastically reduced in those
sections and cells receiving preabsorbed antibody, confirming
antibody specificity (Fig. 1B).
Endogenous CHIP Localizes to -Synuclein Inclusions in Cell
Culture—Coexpression of a C-terminally tagged -synuclein
construct (Syn-T) with synphilin-1 in human H4 neuroglioma
cells leads to the development of -synuclein-immunopositive
inclusions in 50% of transfected cells (26, 36, 39). In the
current study, we used immunofluorescence to examine the
distribution of CHIP in Syn-T- and synphilin-1-transfected
cells. All -synuclein-immunopositive inclusions identified
were immunoreactive for endogenous CHIP and endogenous
Hsp70 (Fig. 2A). When CHIP, CHIPU, or CHIPTPR (Fig.
2B) was cotransfected with Syn-T and synphilin-1 we detected
a robust up-regulation of endogenous Hsp70 expression in
CHIP or CHIPU- but not CHIPTPR-transfected cells com-
pared with control vector transfected cells with Western blot
analysis (Fig. 2C). The fact that cotransfection of CHIP resulted
in an up-regulation of endogenous Hsp70 is consistent with the
idea that CHIP and Hsp70 are co-regulated (17, 21, 28).
CHIP Suppresses -Synuclein Inclusion Formation and
Changes the Morphology of -Synuclein Inclusions in Cell Cul-
ture—We have previously shown that overexpression of Hsp70
and molecular chaperone-related proteins prevents -synuclein
inclusion formation in human H4 neuroglioma cells (39, 41).
Since CHIP is known to be a co-chaperone that interacts with
Hsp70 and regulates its chaperone activity (28), we tested the
effect of CHIP on -synuclein inclusion formation in H4 cells.
CHIP or deletion mutant CHIP constructs were cotransfected
with Syn-T and synphilin-1, and the number of cells containing
-synuclein-immunopositive inclusions was assessed 48 h after
transfection. Interestingly, CHIP reduced the number of cells
containing -synuclein inclusions by 61.9% (p  0.05) (Fig. 3A).
Surprisingly, a decrease in the number of cells with -synuclein
inclusions was also seen following cotransfection with both
CHIP deletion mutants, CHIPU (U-box deleted) and
CHIPTPR (TPR domain deleted). Furthermore, cotransfec-
tion with CHIP also led to a dramatic change in the morphology
of -synuclein inclusions (Fig. 3B, panels A and B). Immuno-
staining revealed that cotransfection with CHIP resulted in a
switch from several large inclusions (Fig. 3B, panel A) to nu-
merous small inclusions/microaggregates throughout the cyto-
plasm of cells (Fig. 3B, panel B). This morphological change in
inclusion type appeared to be TPR domain-dependent, because
we observed the same tendency when CHIPU (containing the
TPR domain) was cotransfected (Fig. 3B, panel C). However,
when CHIPTPR (containing the U-box domain) was cotrans-
fected, the majority of cells were indistinguishable from control
(i.e. had larger inclusions) (Fig. 3B, panel D). Quantitation of
inclusion size revealed that in SynT- and synphilin-1-trans-
fected cells, 39% of cells with inclusions had predominantly
large inclusions (2.5-m diameter). Cotransfection of CHIP
and CHIPU dramatically reduced the number of cells with
large inclusions to 4.7 and 2.3%, respectively, whereas when
CHIPTPR was cotransfected, 28.6% of cells with inclusions
had large inclusions (Fig. 3C).
CHIP Degrades -Synuclein via the Proteasomal and the
Lysosomal Degradation Pathways—Recent data demonstrated
that CHIP interacts with heat shock proteins and directs sub-
strates of heat shock proteins away from a refolding pathway
FIG. 1. CHIP colocalizes with -synuclein in Lewy bodies in
DLB. A, four pathologically confirmed cases of DLB were triple immu-
nostained with -synuclein, Hsp70, and CHIP. Approximately 87 
7.08% (S.D., n  4) of LBs were immunopositive for CHIP. The scale bar
represents 10 m. B, preabsorption of anti-CHIP antibody with recom-
binant CHIP protein was used as a negative control for the antibody
specificity. DLB tissue (A–D) and H4 cells (E–H) expressing SynT and
CHIP was immunostained with anti--synuclein and either anti-CHIP
(A, B, E, and F) or preabsorbed (C, D, G, and H) anti-CHIP antibody.
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toward the ubiquitin-proteasome degradation pathway (20, 21,
30, 31). We next examined whether CHIP inhibition of
-synuclein inclusion formation is via enhanced protein degra-
dation. H4 cells were cotransfected with Syn-T, synphilin-1,
and either CHIP, CHIPU, or CHIPTPR, and total Syn-T
expression was analyzed by quantifying the 27-kDa Syn-T
band on SDS-PAGE (Fig. 4A). Cotransfection with CHIP sig-
nificantly reduced Syn-T expression by 70  5.7% (S.E., n  6)
compared with control. Cotransfection of CHIPU or
CHIPTPR also decreased Syn-T protein level by 78  7.0%
(S.E., n  6) and 65  8.8% (S.E., n  6), respectively. In
parallel experiments, we also examined the impact of CHIP
overexpression on WT -synuclein, which does not form visible
inclusions in H4 cells. Cotansfection with CHIP or either dele-
tion mutant construct also reduced WT -synuclein protein
expression. These data suggest that CHIP reduces -synuclein
aggregation by enhancing degradation and that either the TPR
domain or U-box domain is sufficient for the effect of CHIP.
To determine that the decrease in Syn-T protein levels is a
result of enhanced degradation and not transcriptional down-
regulation, we used a tetracycline-regulated stably transfected
cell line expressing SynT to assess the degradation kinetics.
Stably transfected cells were maintained in the absence of
doxycycline, which results in the overexpression of Syn-T. Fol-
lowing cotransfection of synphilin-1 and CHIP or control empty
vector, the cells were treated with 1 g/ml doxycycline to sup-
press -synuclein expression. Cells were harvested at specific
time points (0, 3, 6, and 12 h), and the level of Syn-T was
assessed via Western blot analysis. When CHIP was co-ex-
pressed, we detected a significantly faster degradation of Syn-T
compared with control transfected cells (Fig. 4B).
To determine the mechanism by which CHIP enhances
-synuclein degradation, we used a selective inhibitor of the 20
S proteasome, ALLN. Syn-T, synphilin-1, and CHIP were co-
expressed in H4 cells and treated with 10 g/ml ALLN for the
last 16–18 h of a 48-h transfection. Interestingly, ALLN treat-
ment prevented CHIPU-mediated degradation of -synuclein,
consistent with a critical role for the TPR domain (and hence
CHIP-HSP interaction) in directing substrate toward the pro-
teasome. However, we found that both full-length CHIP and
CHIPTPR were still able to degrade -synuclein, although the
proteasomal degradation pathway was blocked by ALLN (Fig.
5A), suggesting a proteasome-independent mechanism of
CHIP-mediated degradation.
Recent studies have suggested that lysosomal degradation
may also play an important role in -synuclein degradation and
that mutant -synuclein could prevent chaperone-mediated au-
tophagy, a specific type of lysosomal degradation (42). To in-
vestigate whether CHIP can also mediate -synuclein degra-
dation via the lysosome, we used ammonium chloride (NH4Cl),
an inhibitor of lysosomal proteolysis (43). 25 mM NH4Cl treat-
ment prevented CHIPTPR-mediated degradation (Fig. 5B),
FIG. 2. Endogenous CHIP colocal-
izes with -synuclein inclusions in
H4 cells and overexpression of CHIP
induces endogenous Hsp70 expres-
sion. A, H4 cells were cotransfected with
Syn-T and synphilin-1 and immuno-
stained for -synuclein, Hsp70, and
CHIP. Endogenous Hsp70 and CHIP co-
localized with -synuclein immunoposi-
tive inclusions. The scale bar represents
10 m. B, schematic representation of the
domain structure of CHIP and deletion
mutant CHIP constructs. C, overexpres-
sion of CHIP and CHIPU induced en-
dogenous Hsp70 expression. H4 cells
were transfected with Syn-T, synphilin-1,
and either control vector, CHIP, CHIPU,
or CHIPTPR, and total cell lysate was
analyzed for Hsp70. Band densities were
quantified using the Odyssey infrared im-
aging system, normalized to actin to con-
trol for loading errors, and expressed as
-fold above control. Data are presented
as means  S.E. of four independent
experiments.
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consistent with a role for the U-box domain of CHIP to direct
-synuclein toward the lysosome. However, both full-length
CHIP and CHIPU were still able to degrade -synuclein,
although the lysosomal degradation pathway was blocked, con-
sistent with our previous data indicating that CHIP can also
mediate degradation via the proteasome.
Previous studies have found that CHIP directly interacts
with Hsp70 via its TPR domain to regulate chaperone activity
and directly interacts with Parkin to positively regulate its E3
ubiquitin ligase activity. To decipher the mechanism by which
CHIP mediates -synuclein degradation, we performed coim-
munoprecipitation experiments whereby H4 cells were trans-
fected with Myc-tagged CHIP, Syn-T, and synphilin-1 and im-
munoprecipitated using an anti-Myc antibody. Western blot
analysis revealed that Syn-T, synphilin-1, and endogenous
Hsp70 could all be coimmunoprecipitated with CHIP (Fig. 6).
By contrast, CHIPTPR failed to coimmunoprecipitate Hsp70,
confirming the fact that the TPR domain of CHIP is required
for interactions with Hsp70 and suggesting that Hsp70 is not
required for CHIP-mediated lysosomal degradation. Moreover,
when H4 cells were transfected with Myc-tagged CHIP and
Syn-T, without synphilin-1, CHIP could still immunoprecipi-
tate Syn-T, suggesting the possibility of a direct CHIP-
synuclein interaction, although facilitation by another member
of the co-chaperone complex cannot be excluded.
DISCUSSION
In the present study, we tested the hypothesis that CHIP, a
dual function protein (cochaperone and E3 ubiquitin ligase),
can modulate -synuclein inclusion formation. Here, we dem-
onstrate that 1) CHIP is a component of Lewy bodies; 2) CHIP
colocalizes with Hsp70 and -synuclein in LB-like inclusions in
vitro; 3) CHIP can reduce -synuclein inclusions in vitro; 4)
CHIP changes the morphology of -synuclein inclusions in
vitro; 5) CHIP enhances -synuclein degradation by two mech-
anisms (via the proteasome in a TPR domain-dependent man-
ner and via the lysosomal degradation pathway that is depend-
ent on the U-box domain); and 6) CHIP, -synuclein,
synphilin-1, and Hsp70 exist as a complex.
Misfolding and aggregation of -synuclein is thought to be a
critical cofactor in the pathogenesis of LB related neurodegen-
erative diseases. Several proteins associated with misfolding
and aggregation have been found to deposit in LBs in DLB and
Parkinson disease brains, including chaperone-related proteins
like 14-3-3 (44); heat shock proteins, including Hsp70 and
Hsp40 (16, 39); and ubiquitin degradation pathway-related
proteins like parkin (45, 46), UCH-L1 (47), ubiquitin (48, 49),
and proteasomal subunits (50). This raises the possibility that
the cellular machinery that recognizes and handles abnormally
folded proteins may be involved in these diseases. Here, we
demonstrate that CHIP accumulates in LBs in DLB brain.
CHIP has been shown to interact with Hsp70/Hsc70 and facil-
itate the degradation of misfolded proteins (20, 21, 30, 31).
Taken together, the presence of CHIP in LBs supports a role in
protein misfolding and aggregation related to LB formation in
the synucleinopathies. These data are consistent with the re-
cent observation that CHIP is present in tau lesions in human
postmortem tissue (33, 51), further implicating CHIP in neu-
rodegenerative disease where protein misfolding is central to
the disease pathogenesis.
Consistent with our observation that LBs contain CHIP, we
also found that endogenous CHIP colocalized with -synuclein
and Hsp70 in intracellular inclusions in H4 human neurogli-
oma cells. In addition, we found that overexpression of CHIP or
CHIPU up-regulated endogenous Hsp70. CHIP has been
identified as an Hsp70-interacting protein (28), and overex-
pression of Hsp70 has been shown to decrease -synuclein
inclusion formation in H4 cells (26, 39) and reduce high molec-
ular weight, aggregated -synuclein in vivo and in vitro (26).
These data suggest that a functional interaction exists between
CHIP and Hsp70, which combines chaperone-mediated refold-
ing and proteasomal and lysosomal degradation, to modulate
-synuclein aggregation.
Coexpression of Hsp70 reduces the number of cells contain-
ing -synuclein inclusions (26, 39). Here, we found that CHIP
not only reduced the number of cells containing -synuclein
FIG. 3. Overexpression of CHIP suppresses -synuclein inclu-
sion formation and dramatically changes the morphology of
-synuclein inclusions in H4 cells. A, H4 cells were cotransfected
with Syn-T, synphilin-1, and either CHIP, CHIPU, or CHIPTPR and
immunostained for -synuclein. 48 h after transfection, the number of
cells containing -synuclein-immunopositive inclusions were assessed
as described in methods section. Data are presented as means  S.E. of
three independent experiments. B, cotransfection of SynT and synphi-
lin-1 with CHIP (B) or CHIPU (C) resulted in a decrease in inclusion
size, whereas CHIPTPR (D) resulted in inclusions with morphology
similar to control (A). The scale bar represents 10 m. C, quantitation
of the number of cells containing large (2.5-m diameter) -synuclein-
immunopositive inclusions following cotransfection with CHIP,
CHIPU, or CHIPTPR. Data are presented as means  S.E. of four
independent experiments. **, p  0.0001; *, p  0.02 compared with
control.
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inclusions but also produced a striking effect on inclusion mor-
phology, shifting them from large inclusions to small inclusions
throughout the cytoplasm. This change in morphology was TPR
domain-dependent, which supports the idea that CHIP modu-
lates the effect of Hsp70 on -synuclein inclusions. This change
in morphology was not concentration-dependent, because large
inclusions were also observed when Syn-T expression was de-
creased using a tetracycline-regulated transfection system.2
Recently, Lee et al. reported that overexpression of -synuclein
produces two distinct subtypes of inclusions: large fibrillar
juxtanuclear inclusion bodies and small nonfibrillar punctuate
aggregates scattered throughout the cytoplasm. They sug-
gested that the inclusions appeared sequentially; small aggre-
gates appeared first as a nucleation protofibril progressing to
large fibrillar inclusions (52). It is not clear at this time if the
small microaggregates of -synuclein observed in the presence
of CHIP represent nucleation protofibrils that have been
blocked from proceeding to large inclusions or if they represent
intermediate aggregates in the process of protein degradation.
Further experiments will be required to clarify this process.
Our observation that overexpression of CHIP, CHIPU, or
CHIPTPR could all decrease -synuclein protein expression
suggests that either the TPR domain or U-box domain alone is
sufficient for CHIP to facilitate -synuclein degradation. CHIP
has been demonstrated to facilitate the degradation of chaperone
substrates via the ubiquitin-dependent proteasomal degradation
pathway in a U-box-dependent manner (30–32), so it is intrigu-
ing that CHIPU could also degrade -synuclein when the E3
ubiquitin ligase activity conferring domain is deleted. This sug-
gests that an additional degradation pathway for CHIP-mediated
degradation of -synuclein exists. This hypothesis is supported
by the fact that the facilitation by CHIP of -synuclein degrada-
tion was not reversed by proteasome inhibitor.
Most long lived proteins (half-life 5 h) are degraded in the
lysosome and vacuole lytic compartments. Autophagy is a ma-
jor cellular route to transport cytoplasmic proteins to the lyso-
some for degradation. Autophagic degeneration has been de-
tected in the neurons of the substantia nigra in Parkinson
disease patients (53) and Alzheimer disease (54). Here, we
show that CHIP mediates -synuclein degradation via the ly-
sosome and that the U-box domain is required, suggesting that
E3 ubiquitin ligase activity is involved in the lysosomal degra-
dation pathway. Recently, several lines of evidence have
emerged to suggest that ubiquitin-dependent protein traffick-
ing usually requires the ligation of just one single ubiquitin to
the substrate through ubiquitin Lys63 (55, 56). This monoubiq-
uitination participates in targeting proteins to endosomal com-
partments either from the plasma membrane (57) or from the
trans-Golgi network (58) and is also involved in protein sorting
from endosome to multivesicular bodies and in delivery of
transmembrane proteins into the lysosomal/vacuolar compart-
ment (59).
That the TPR domain of CHIP is required for -synuclein
degradation via the proteasome indicates that a CHIP-Hsp70
interaction may be required to target -synuclein to the pro-
teasome. In support of this hypothesis, recent data have shown
that CHIP cooperates with Hsc70/Hsp70 and Hsp90 for substrate
targeting to the proteasome (31, 60, 61). CHIP has also been
shown to inhibit Hsp70-mediated refolding of luciferase (28).
Taken together, we propose that CHIP inhibits -synuclein in-
clusion formation by redirecting Hsp70 from protein refolding to
protein degradation. In Lewy bodies, this process may fail.
The fact that -synuclein, synphilin-1, and Hsp70 coimmu-
noprecipitate with CHIP raises the possibility that CHIP may
directly interact with -synuclein or that a protein complex
may exist. These data are consistent with the recent observa-
tion that CHIP specifically interacts with and degrades ex-
panded polyglutamine proteins (62). Further studies will be
required to determine the nature of the complex.
In sum, our data show that CHIP is associated with
-synuclein inclusions both in vivo and in vitro and that CHIP
acts as a co-chaperone, altering -synuclein aggregation and
enhancing the degradation of misfolded -synuclein. Impor-
tantly, we suggest for the first time that CHIP can direct
degradation via either a TPR domain dependent proteasomal
2 Y. Shin, J. Klucken, C. Patterson, B. T. Hyman, and P. J. McLean,
unpublished observation.
FIG. 4. CHIP mediates -synuclein
degradation. A, H4 cells were cotrans-
fected with Syn-T, synphilin-1, and either
empty vector, CHIP, CHIPU, or
CHIPTPR. Total Syn-T expression was
analyzed by quantifying the 27-kDa
Syn-T band on SDS-PAGE compared with
control transfected cells. Syn-T expres-
sion was normalized to actin expression.
Band densities were quantified using Od-
yssey infrared imaging system and ex-
pressed as -fold above control. Data are
presented as means  S.E. of four inde-
pendent experiments. Statistical analysis
was done by one group t test for signifi-
cance at the p  0.05 level. B, Tet-regu-
lated H4 cells stably overexpressing
Syn-T were cotransfected with synphi-
lin-1 and either empty vector or CHIP.
16 h after transfection, 1 g/ml doxycy-
cline was added in culture medium to
turn off the Syn-T expression, and cells
were harvested at the indicated time
points. Syn-T expression was analyzed by
Western blot analysis and quantified us-
ing imageJ analysis software. Data are
presented as means  S.E. of three inde-
pendent experiments. Statistical analysis
was done by linear regression analysis for
significance at the p  0.05 level.
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pathway or a U-box dependent lysosomal pathway. Insofar as the
balance of aggregation/degradation of misfolded -synuclein
may be critical in the synucleinopathies, CHIP and related
heat shock protein co-chaperone molecules may play critical
regulatory roles.
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